Boston Scientific (BSX)
Builds minimally invasive devices for cardiovascular, endoscopic, urological and neuromodulation procedures.
$44.26
vs last close−0.66 (−1.47%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,527 | 3,725 | 3,856 | 4,120 | 4,209 | 4,561 | 4,663 | 5,061 | 5,065 | 5,286 | 5,203 | 5,442 |
| Cost of revenue | 1,360 | 1,413 | 1,472 | 1,535 | 1,561 | 1,890 | 1,713 | 1,637 | 1,523 | 1,348 | 1,590 | 1,594 |
| Gross profit | 2,167 | 2,312 | 2,384 | 2,585 | 2,648 | 2,671 | 2,950 | 3,424 | 3,542 | 3,937 | 3,613 | 3,848 |
| 1,609 | 1,754 | 1,740 | 1,838 | 1,974 | 2,082 | 2,054 | 2,605 | 2,492 | 2,731 | 2,541 | 2,670 | |
| Research & development | 356 | 363 | 366 | 383 | 407 | 460 | 443 | 526 | 514 | 569 | 516 | 554 |
| Selling, general & administrative | 1,242 | 1,379 | 1,364 | 1,446 | 1,562 | 1,612 | 1,597 | 1,716 | 1,741 | 1,834 | 1,781 | 1,803 |
| Other expenses | 11 | 12 | 10 | 9 | 5 | 10 | 14 | 363 | 237 | 328 | 244 | 313 |
| Operating income | 558 | 558 | 644 | 747 | 674 | 589 | 896 | 819 | 1,050 | 1,206 | 1,072 | 1,178 |
| 51 | −53 | −36 | −327 | −6 | −4 | −91 | 122 | −111 | −506 | 90 | −118 | |
| Interest income | 0 | 22 | 0 | 0 | 0 | 22 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 67 | 67 | 72 | 81 | 83 | 139 | 87 | 90 | 87 | 90 | 90 | 96 |
| Other non-operating income | −117 | −14 | −36 | 246 | −77 | −134 | 4 | −212 | 24 | 250 | −180 | 22 |
| Income before tax | 609 | 505 | 608 | 420 | 668 | 585 | 805 | 941 | 939 | 700 | 1,162 | 1,060 |
| Income tax expense | 105 | 1 | 115 | 98 | 200 | 23 | 133 | 146 | 183 | 31 | −176 | 155 |
| Net income from continuing operations | 504 | 504 | 493 | 322 | 468 | 562 | 672 | 795 | 756 | 669 | 1,338 | 905 |
| Other adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 1 | 4 |
| Net income | 504 | 504 | 494 | 324 | 469 | 566 | 674 | 793 | 755 | 668 | 1,337 | 907 |
| EPS, basic | $0.34 | $0.34 | $0.34 | $0.22 | $0.32 | $0.38 | $0.46 | $0.54 | $0.51 | $0.45 | $0.90 | $0.62 |
| EPS, diluted | $0.34 | $0.34 | $0.33 | $0.22 | $0.32 | $0.38 | $0.45 | $0.53 | $0.50 | $0.45 | $0.90 | $0.61 |
| Weighted average shares, basic | 1,465 | 1,465 | 1,468 | 1,471 | 1,473 | 1,474 | 1,477 | 1,479 | 1,482 | 1,483 | 1,485 | 1,478 |
| Weighted average shares, diluted | 1,475 | 1,477 | 1,482 | 1,484 | 1,487 | 1,490 | 1,493 | 1,493 | 1,496 | 1,496 | 1,495 | 1,485 |
| EBITDA | 976 | 885 | 984 | 812 | 1,058 | 1,071 | 1,217 | 1,367 | 1,368 | 1,321 | 1,603 | 1,389 |
| Depreciation & amortization | 301 | 313 | 304 | 311 | 307 | 348 | 325 | 336 | 342 | 365 | 351 | 233 |
| EBIT | 675 | 572 | 680 | 501 | 751 | 723 | 892 | 1,032 | 1,026 | 956 | 1,252 | 1,156 |